In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Nipro Corp.

New Japan PMDA Head Brings Strong Clinical, Patient Focus To Role

The main priorities for the new chief executive of Japan’s drugs regulator over the next five years include putting patients first by promoting early access while ensuring safety, further strengthening pharmacovigilance as new forms of therapy come through, and increasing collaboration with Asia, as the agency looks to meet the challenges of changing technologies.

Market Access Regulation

New Japan PMDA Head Brings Strong Clinical, Patient Focus To Role

The main priorities for the new chief executive of Japan’s drugs regulator over the next five years include putting patients first by promoting early access while ensuring safety, further strengthening pharmacovigilance as new forms of therapy come through, and increasing collaboration with Asia, as the agency looks to meet the challenges of changing technologies.

Japan Regulation

Oncology, Orphans Dominate Japan Fiscal 2018 Approvals

Oncology again dominated new drug approvals in Japan last fiscal year, when expedited and special review pathways also played a major role in ensuring early access to new therapies.

Japan Approvals

Kymriah To Set Off Alarms As it Becomes Japan’s Most Expensive Drug?

Novartis CAR-T therapy becomes most expensive drug ever covered by Japan’s national health insurance system. Although authorities expect total sales to be modest, might high price again raise official concerns over ballooning health costs?

Japan Government Payers
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Implantable Devices
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Nipro Corp.
  • Senior Management
  • Yoshihiko Sano, Pres.
  • Contact Info
  • Nipro Corp.
    Phone: (81) 6 6372 2331
    3-9-3 Honjo-nishi, Kita-ku
    Osaka, 531-8510
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register